News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
162,482 Results
Type
Article (6777)
Company Profile (45)
Press Release (155660)
Section
Business (48709)
Career Advice (476)
Deals (9556)
Drug Delivery (15)
Drug Development (34094)
Employer Resources (20)
FDA (4394)
Job Trends (3743)
News (93057)
Policy (6551)
Tag
Academia (496)
Alliances (8120)
Alzheimer's disease (454)
Approvals (4384)
Artificial intelligence (22)
Bankruptcy (64)
Best Places to Work (3399)
Biotechnology (36)
Breast cancer (52)
Cancer (390)
Career advice (373)
Cell therapy (63)
Clinical research (28093)
Collaboration (84)
COVID-19 (719)
Cystic fibrosis (25)
Data (450)
Diabetes (59)
Diagnostics (1509)
Drug discovery (22)
Earnings (30823)
Events (27114)
Executive appointments (45)
FDA (4570)
Funding (85)
Gene therapy (51)
GLP-1 (254)
Government (855)
Healthcare (4754)
Infectious disease (738)
Inflammatory bowel disease (39)
Interviews (88)
IPO (5813)
Job creations (494)
Job search strategy (325)
Layoffs (54)
Legal (865)
Liver cancer (26)
Lung cancer (76)
Manufacturing (30)
Medical device (2798)
Medtech (2798)
Mergers & acquisitions (3792)
Metabolic disorders (126)
Neuroscience (556)
NextGen Class of 2024 (1255)
Non-profit (635)
Northern California (457)
Obesity (68)
Opinion (33)
Parkinson's disease (32)
People (7762)
Phase I (8111)
Phase II (13826)
Phase III (9055)
Pipeline (118)
Postmarket research (886)
Preclinical (2581)
Radiopharmaceuticals (82)
Rare diseases (55)
Real estate (572)
Regulatory (5235)
Research institute (499)
Resumes & cover letters (96)
Series A (27)
Southern California (387)
Startups (696)
United States (3688)
Vaccines (130)
Weight loss (38)
Date
Last 7 days (277)
Last 30 days (1021)
Last 365 days (13695)
2024 (11021)
2023 (14783)
2022 (17492)
2021 (17689)
2020 (15678)
2019 (11148)
2018 (8294)
2017 (8640)
2016 (7267)
2015 (8838)
2014 (5985)
2013 (4071)
2012 (4255)
2011 (4684)
2010 (4184)
Location
Africa (163)
Asia (10244)
Australia (1705)
California (970)
Canada (435)
China (79)
Colorado (28)
Connecticut (44)
Delaware (30)
Europe (24335)
Florida (121)
Georgia (32)
Illinois (54)
Indiana (59)
Japan (26)
Kansas (30)
Maryland (163)
Massachusetts (707)
Michigan (35)
Minnesota (58)
New Jersey (293)
New York (288)
North Carolina (153)
Northern California (457)
Ohio (29)
Pennsylvania (291)
South America (281)
Southern California (387)
Texas (126)
Washington State (106)
162,482 Results for "a2 biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
A2 Biotherapeutics, Inc. today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.
May 16, 2024
·
3 min read
FDA
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
A2 Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.
March 4, 2024
·
2 min read
BioMidwest
A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
A2 Biotherapeutics, Inc. will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 29, 2024
·
6 min read
Business
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
A2 Biotherapeutics, Inc. today announced the appointment of James Robinson as its Chief Executive Officer and a member of its Board of Directors, effective April 1st , 2024.
March 25, 2024
·
3 min read
Drug Development
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”), (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB.
March 11, 2024
·
7 min read
Press Releases
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
October 25, 2024
·
3 min read
Biotech Beach
A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill.
April 24, 2024
·
3 min read
Press Releases
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
October 18, 2024
·
4 min read
Drug Development
Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023
Revolo Biotherapeutics (“Revolo” or the “Company”) today announced that it will present the previously announced Phase 2a trial data evaluating its immune-resetting drug candidate, ‘1104, in people with eosinophilic esophagitis (EoE), via a poster at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, Canada, from October 20-25.
October 17, 2023
·
2 min read
Drug Development
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics (KQ288330) announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the Phase 2a trial (NCT05483907) evaluating the efficacy, safety, and tolerability of BBT-877 in patients with idiopathic pulmonary fibrosis (IPF).
October 25, 2023
·
4 min read
1 of 16,249
Next
